These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 15251972

  • 21. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.
    Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H, Hu JT, Liu CJ, Lai MY, Chen DS, Yang SS, Kao JH.
    Antivir Ther; 2010; 15(2):177-84. PubMed ID: 20386072
    [Abstract] [Full Text] [Related]

  • 22. Detection of hepatitis B virus polymerase variations resistant to lamivudine therapy.
    Zhang X, Han Y, Lu Z, Zhang D, Cai Y.
    Chin Med J (Engl); 2000 May; 113(5):455-7. PubMed ID: 11776105
    [Abstract] [Full Text] [Related]

  • 23. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 24. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct 15; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 25. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B, Wei L, Chen M, Wang L.
    Microbiol Res; 2008 Oct 15; 163(4):487-92. PubMed ID: 17317127
    [Abstract] [Full Text] [Related]

  • 26. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD.
    J Infect Dis; 1999 Dec 15; 180(6):1757-62. PubMed ID: 10558928
    [Abstract] [Full Text] [Related]

  • 27. [Detection of the mutation in HBV polymerase gene by RFLP PCR method in hepatitis B patients treated with lamivudine].
    Li Z, Guo YB, Hao W, Lin ZH, Jin HY, Liu DG.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep 15; 17(3):266-9. PubMed ID: 15340574
    [Abstract] [Full Text] [Related]

  • 28. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA.
    AIDS; 2007 Aug 20; 21(13):1701-10. PubMed ID: 17690567
    [Abstract] [Full Text] [Related]

  • 29. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
    Hepatology; 2007 May 20; 45(5):1179-86. PubMed ID: 17465002
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.
    AIDS; 2008 Sep 12; 22(14):1779-87. PubMed ID: 18753861
    [Abstract] [Full Text] [Related]

  • 31. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct 12; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

  • 32. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL, Netherlands Association of Gastroenterologists and Hepatologists.
    Neth J Med; 2008 Oct 12; 66(7):292-306. PubMed ID: 18663260
    [Abstract] [Full Text] [Related]

  • 33. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
    Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M.
    J Viral Hepat; 2007 Dec 12; 14(12):835-40. PubMed ID: 18070286
    [Abstract] [Full Text] [Related]

  • 34. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M.
    J Viral Hepat; 2005 Mar 12; 12(2):154-9. PubMed ID: 15720530
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA.
    Eur J Gastroenterol Hepatol; 2008 Aug 12; 20(8):773-7. PubMed ID: 18617782
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.